Nuvalent is a biopharmaceutical company. Co.'s product candidate, NVL-520, is a ROS proto-oncogene 1 (ROS1)-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of available ROS1 tyrosine kinase inhibitors. Co.'s another product candidate, NVL-655, is a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor, designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-, second-, and third-generation ALK inhibitors. We show 5 historical shares outstanding datapoints in our coverage of NUVL's shares outstanding history.
Understanding the changing numbers of NUVL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NUVL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NUVL by allowing them to research NUVL shares outstanding history
as well as any other stock in our coverage universe. |
Free NUVL Email Alerts:
Video: Shares Outstanding Importance
